Expert Cancer Panel: High-risk MDS w/ excess blasts-2 diagnostics and management

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Recorded on 10/9/2021

High-risk MDS with excess blasts-2 diagnostics and management

Summary:
- For a patient with high-risk MDS evolving to AML, with complex karyotype and deletion 17p with likely TP53 mutation, the panel recommends hypomethylating agent, such as decitabine and azacitidine, with venetoclax for induction as well as early evaluation for allogeneic stem cell transplant in remission.
- Vyxeos and 7+3 intensive chemotherapy would also be options to consider depending on the patient’s medical comorbidities, age, and performance status.


At PrecisCa, we are dedicated to providing expert second opinions for cancer patients to ensure they receive the best possible care. Our videos cover a wide range of topics related to oncology, including in-depth discussions on different types of cancer, treatment options, patient stories, and the latest advancements in cancer research. Whether you're a patient, caregiver, or simply seeking to expand your knowledge, our goal is to support you on your healthcare journey.

Visit our website: https://www.PrecisCa.com for more detailed information and personalized second opinions.

Stay connected with us:
Facebook: / precisca.oncology
Twitter: https://twitter.com/precisca_?lang=en
-Instagram: / precisca_oncology
-LinkedIn: / precisca

Don't forget to subscribe to our channel for regular updates and new videos. Hit the bell icon to receive notifications every time we upload. #Oncology #CancerCare #CancerSupport #CancerResearch #Health #Healthcare #CancerTreatment #CancerAwareness #PatientCare #MedicalAdvice #PrecisCa
Category
Oncology
Be the first to comment

Up Next